csirt@kutim:~/threat-intel/cve/CVE-2026-44451

Katalog CVE

CVSS 9.3 · Critical EPSS 0,41%

Kerentanan Protection Mechanism Failure. Skor CVSS 3.1 9.3 (Critical) menurut github.com.

Deskripsi (NVD)

Lumiverse is a full-featured AI chat application. Prior to 0.9.7, the component override system transpiles user-supplied TSX via Sucrase and evaluates it with new Function, shadowing dangerous globals (fetch, window, eval, etc.) with undefined. A static source validator (validateComponentOverrideSource) additionally blocks these identifiers by word-boundary regex. Both controls are bypassed. String-split bypass of the static validator: any blocked identifier can be reconstructed at runtime from string fragments ('ownerDoc' + 'ument'). DOM ref escape from the sandbox: useRef and useEffect are provided in scope. A ref attached to a rendered element gives a live DOM node. From any real DOM node, node['ownerDoc'+'ument']['def'+'aultView'] yields the real window, bypassing all identifier shadows. Theme packs (.lumitheme / .lumiverse-theme) are the shareable delivery mechanism. A malicious pack is an exploit path: the victim imports the file, enables one component override in the Theme Editor, and the payload fires in their authenticated session.This vulnerability is fixed in 0.9.7.

Rincian

Terbit di NVD
26 Mei 2026
Terakhir diubah
24 Juli 2026
Status NVD
Deferred
CVSS 3.1
9.3 (Critical), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-693: Protection Mechanism Failure
EPSS (30 hari)
0,41% peluang dieksploitasi; lebih tinggi dari 33,2% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.